Ranibizumab

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uveitis Related Cystoid Macular Edema

Conditions

Uveitis Related Cystoid Macular Edema, Steroid-induced Glaucoma - Borderline

Trial Timeline

May 1, 2012 → Jun 1, 2014

NCT ID

NCT01564108

About Ranibizumab

Ranibizumab is a phase 2 stage product being developed by Novartis for Uveitis Related Cystoid Macular Edema. The current trial status is completed. This product is registered under clinical trial identifier NCT01564108. Target conditions include Uveitis Related Cystoid Macular Edema, Steroid-induced Glaucoma - Borderline.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis Related Cystoid Macular Edema were approved

Approved (3) Terminated (8) Active (9)

🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3

🔄Baricitinib + AdalimumabEli LillyPhase 3

✅Ixekizumab Prefilled SyringeEli LillyApproved

🔄adalimumabAbbViePhase 3

🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

✅AdalimumabAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04464694	Approved	UNKNOWN	Sep 1, 2020	Jun 1, 2022	Proliferative Diabetic Retinopathy
NCT02953938	Approved	Completed	Dec 15, 2016	Dec 28, 2018	Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
NCT02976194	Approved	UNKNOWN	Nov 22, 2016	Jan 1, 2020	Exudative Age-related Macular Degeneration
NCT02843490	Approved	Completed	Aug 5, 2016	Nov 9, 2017	Neovascular Age-related Macular Degeneration
NCT02640664	Phase 3	Completed	Jun 16, 2016	Apr 21, 2022	Retinopathy of Prematurity (ROP)
NCT02707575	Pre-clinical	Completed	Apr 26, 2016	Apr 23, 2018	Age-related Macular Degeneration
NCT02634970	Approved	Withdrawn	Mar 1, 2016	Dec 1, 2017	Wet Age-related Macular Degeneration (Wet AMD)
NCT02375971	Phase 3	Completed	Dec 30, 2015	Dec 14, 2017	Retinopathy of Prematurity
NCT02329132	Pre-clinical	Completed	Nov 1, 2015	Feb 28, 2018	Diabetic Macular Edema
NCT02161575	Approved	Completed	Aug 28, 2014	Sep 14, 2017	Neovascular Age-related Macular Degeneration
NCT02034006	Phase 3	Completed	Jun 10, 2014	Jul 15, 2016	Choroidal Neovascularization Secondary to Pathologic Myopia
NCT02059772	Approved	UNKNOWN	Apr 30, 2014	Dec 31, 2017	Diabetic Macular Edema
NCT01986907	Approved	Completed	Mar 4, 2014	Jun 15, 2016	Wet Age Related Macular Degeneration
NCT02055911	Approved	Withdrawn	Mar 1, 2014	Jul 1, 2015	Diabetic Macular Edema
NCT02478515	Approved	Completed	Jan 1, 2014	Mar 1, 2019	Branch Retinal Vein Occlusion
NCT01972789	Approved	Completed	Oct 31, 2013	Feb 28, 2017	Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
NCT01846299	Phase 3	Completed	Oct 1, 2013	Sep 1, 2015	Macular Edema (ME)
NCT01908816	Phase 3	Completed	Sep 26, 2013	Jan 8, 2016	Choroidal Neovascularization
NCT01840410	Phase 3	Completed	Sep 1, 2013	Nov 1, 2015	Choroidal Neovascularization (CNV)
NCT01780935	Phase 3	Completed	Jun 3, 2013	Jul 9, 2015	Neovascular Age-related Macular Degeneration

Competing Products

20 competing products in Uveitis Related Cystoid Macular Edema

See all competitors

Product	Company	Stage	Hype Score
triamcinolone acetonide (Triesence®)	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA Suprachoriodal Injection	Clearside Biomedical	Phase 3	30
Baricitinib + Adalimumab	Eli Lilly	Phase 3	44
Ixekizumab Prefilled Syringe	Eli Lilly	Approved	39
adalimumab	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab	AbbVie	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
AIN457	Novartis	Phase 3	32
Myfortic	Novartis	Pre-clinical	22
AIN457 + AIN457 + Placebo AIN457	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AEB071	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
Myfortic + Decortin	Novartis	Phase 3	40
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32